Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease

Simon Royce, Yu Miao, Melissa Lee, Chrishan Samuel, Geoffrey Tregear, Mimi Tang

Research output: Contribution to journalArticleResearchpeer-review

29 Citations (Scopus)

Abstract

Mice deficient in the antifibrotic hormone relaxin develop structural changes in the airway that resemble airway remodeling, and demonstrate exaggerated remodeling changes in models of allergic airways disease (AAD). Relaxin expression in asthma has not been previously studied. We evaluated the efficacy of relaxin in the treatment of established airway remodeling in a mouse model of AAD. Relaxin expression in mouse AAD was also examined by immunohistochemistry and real-time PCR. BALB/c mice with established AAD were treated with relaxin or vehicle control (sc for 14 d), and effects on airway remodeling, airway inflammation, and airway hyperresponsiveness (AHR) were assessed. Relaxin expression was significantly reduced in the airways of mice with AAD compared with controls. Recombinant relaxin treatment in a mouse model of AAD reversed collagen deposition and epithelial thickening, and significantly improved AHR (all P <0.05 vs. vehicle control), but did not influence airway inflammation or goblet cell hyperplasia. Relaxin treatment was associated with increased matrix metalloproteinase-2 levels, suggesting a possible mechanism for its antifibrotic effects. Endogenous relaxin expression is decreased in murine AAD, whereas exogenous relaxin represents a novel treatment capable of reversing established airway remodeling and AHR.
Original languageEnglish
Pages (from-to)2692 - 2699
Number of pages8
JournalEndocrinology
Volume150
Issue number6
DOIs
Publication statusPublished - 2009
Externally publishedYes

Cite this

Royce, Simon ; Miao, Yu ; Lee, Melissa ; Samuel, Chrishan ; Tregear, Geoffrey ; Tang, Mimi. / Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease. In: Endocrinology. 2009 ; Vol. 150, No. 6. pp. 2692 - 2699.
@article{d6ec2df0f1f947568f22307238fec526,
title = "Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease",
abstract = "Mice deficient in the antifibrotic hormone relaxin develop structural changes in the airway that resemble airway remodeling, and demonstrate exaggerated remodeling changes in models of allergic airways disease (AAD). Relaxin expression in asthma has not been previously studied. We evaluated the efficacy of relaxin in the treatment of established airway remodeling in a mouse model of AAD. Relaxin expression in mouse AAD was also examined by immunohistochemistry and real-time PCR. BALB/c mice with established AAD were treated with relaxin or vehicle control (sc for 14 d), and effects on airway remodeling, airway inflammation, and airway hyperresponsiveness (AHR) were assessed. Relaxin expression was significantly reduced in the airways of mice with AAD compared with controls. Recombinant relaxin treatment in a mouse model of AAD reversed collagen deposition and epithelial thickening, and significantly improved AHR (all P <0.05 vs. vehicle control), but did not influence airway inflammation or goblet cell hyperplasia. Relaxin treatment was associated with increased matrix metalloproteinase-2 levels, suggesting a possible mechanism for its antifibrotic effects. Endogenous relaxin expression is decreased in murine AAD, whereas exogenous relaxin represents a novel treatment capable of reversing established airway remodeling and AHR.",
author = "Simon Royce and Yu Miao and Melissa Lee and Chrishan Samuel and Geoffrey Tregear and Mimi Tang",
year = "2009",
doi = "10.1210/en.2008-1457",
language = "English",
volume = "150",
pages = "2692 -- 2699",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "Endocrine Society",
number = "6",

}

Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease. / Royce, Simon; Miao, Yu; Lee, Melissa; Samuel, Chrishan; Tregear, Geoffrey; Tang, Mimi.

In: Endocrinology, Vol. 150, No. 6, 2009, p. 2692 - 2699.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease

AU - Royce, Simon

AU - Miao, Yu

AU - Lee, Melissa

AU - Samuel, Chrishan

AU - Tregear, Geoffrey

AU - Tang, Mimi

PY - 2009

Y1 - 2009

N2 - Mice deficient in the antifibrotic hormone relaxin develop structural changes in the airway that resemble airway remodeling, and demonstrate exaggerated remodeling changes in models of allergic airways disease (AAD). Relaxin expression in asthma has not been previously studied. We evaluated the efficacy of relaxin in the treatment of established airway remodeling in a mouse model of AAD. Relaxin expression in mouse AAD was also examined by immunohistochemistry and real-time PCR. BALB/c mice with established AAD were treated with relaxin or vehicle control (sc for 14 d), and effects on airway remodeling, airway inflammation, and airway hyperresponsiveness (AHR) were assessed. Relaxin expression was significantly reduced in the airways of mice with AAD compared with controls. Recombinant relaxin treatment in a mouse model of AAD reversed collagen deposition and epithelial thickening, and significantly improved AHR (all P <0.05 vs. vehicle control), but did not influence airway inflammation or goblet cell hyperplasia. Relaxin treatment was associated with increased matrix metalloproteinase-2 levels, suggesting a possible mechanism for its antifibrotic effects. Endogenous relaxin expression is decreased in murine AAD, whereas exogenous relaxin represents a novel treatment capable of reversing established airway remodeling and AHR.

AB - Mice deficient in the antifibrotic hormone relaxin develop structural changes in the airway that resemble airway remodeling, and demonstrate exaggerated remodeling changes in models of allergic airways disease (AAD). Relaxin expression in asthma has not been previously studied. We evaluated the efficacy of relaxin in the treatment of established airway remodeling in a mouse model of AAD. Relaxin expression in mouse AAD was also examined by immunohistochemistry and real-time PCR. BALB/c mice with established AAD were treated with relaxin or vehicle control (sc for 14 d), and effects on airway remodeling, airway inflammation, and airway hyperresponsiveness (AHR) were assessed. Relaxin expression was significantly reduced in the airways of mice with AAD compared with controls. Recombinant relaxin treatment in a mouse model of AAD reversed collagen deposition and epithelial thickening, and significantly improved AHR (all P <0.05 vs. vehicle control), but did not influence airway inflammation or goblet cell hyperplasia. Relaxin treatment was associated with increased matrix metalloproteinase-2 levels, suggesting a possible mechanism for its antifibrotic effects. Endogenous relaxin expression is decreased in murine AAD, whereas exogenous relaxin represents a novel treatment capable of reversing established airway remodeling and AHR.

UR - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19213838

U2 - 10.1210/en.2008-1457

DO - 10.1210/en.2008-1457

M3 - Article

VL - 150

SP - 2692

EP - 2699

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -